• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在酪氨酸激酶抑制剂耐药的慢性髓性白血病中，使用阿西替尼起始治疗时出现难治性全血细胞减少。

Refractory pancytopenia upon initiation of asciminib in tyrosine kinase inhibitor-resistant chronic myeloid leukemia.

作者信息

Tessier Steven, Aiad Mina, Longo Santo, Wilson Melissa, Faroun Yacoub

机构信息

Department of Medicine, St. Luke's University Health Network, Bethlehem, Pennsylvania, USA.

Department of Pathology, St. Luke's University Health Network, Bethlehem, Pennsylvania, USA.

出版信息

Int J Crit Illn Inj Sci. 2023 Apr-Jun;13(2):78-81. doi: 10.4103/ijciis.ijciis_85_22. Epub 2023 Jun 26.

DOI:10.4103/ijciis.ijciis_85_22
PMID:37547190
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10401557/
Abstract

Asciminib, a "Specifically Targeting the ABL Myristoyl Pocket" inhibitor, is a new drug in the treatment of tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML). Hemocytopenias associated with asciminib are common adverse events documented by clinical trials. We report a case of precipitous-onset pancytopenia with the initiation of asciminib treatment in a patient with TKI-resistant CML. This case had a confounding array of laboratory findings that evidenced a drug-induced hemophagocytic component. We hope that our case stimulates further reporting of similar cases to enhance the understanding of the pathophysiology underlying asciminib-induced hemocytopenias.

摘要

阿塞西尼布是一种“特异性靶向ABL肉豆蔻酰口袋”抑制剂，是治疗酪氨酸激酶抑制剂（TKI）耐药慢性粒细胞白血病（CML）的新药。与阿塞西尼布相关的血细胞减少是临床试验记录的常见不良事件。我们报告了1例TKI耐药CML患者在开始阿塞西尼布治疗后突然发生全血细胞减少的病例。该病例有一系列令人困惑的实验室检查结果，证明存在药物诱导的噬血细胞成分。我们希望我们的病例能促使更多类似病例的报告，以加深对阿塞西尼布诱导血细胞减少潜在病理生理学的理解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6777/10401557/f12d4e02cf24/IJCIIS-13-78-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6777/10401557/8676bebc5403/IJCIIS-13-78-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6777/10401557/230e0129fa3b/IJCIIS-13-78-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6777/10401557/f12d4e02cf24/IJCIIS-13-78-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6777/10401557/8676bebc5403/IJCIIS-13-78-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6777/10401557/230e0129fa3b/IJCIIS-13-78-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6777/10401557/f12d4e02cf24/IJCIIS-13-78-g003.jpg

相似文献

1
Refractory pancytopenia upon initiation of asciminib in tyrosine kinase inhibitor-resistant chronic myeloid leukemia.在酪氨酸激酶抑制剂耐药的慢性髓性白血病中，使用阿西替尼起始治疗时出现难治性全血细胞减少。
Int J Crit Illn Inj Sci. 2023 Apr-Jun;13(2):78-81. doi: 10.4103/ijciis.ijciis_85_22. Epub 2023 Jun 26.
2
[Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].[盐酸阿斯科利尼布的药理及临床概况，一种新型的、特异性靶向ABL肉豆蔻酰口袋的一流酪氨酸激酶抑制剂]
Nihon Yakurigaku Zasshi. 2023;158(3):273-281. doi: 10.1254/fpj.22156.
3
An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.评估 ASCIMIB 用于治疗既往接受过≥2 种酪氨酸激酶抑制剂治疗的慢性髓性白血病患者。
Expert Rev Hematol. 2022 Jun;15(6):477-484. doi: 10.1080/17474086.2022.2080049. Epub 2022 May 30.
4
Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.ASCEMBL 研究日本亚组分析：阿西替尼对比博舒替尼用于治疗≥2 种酪氨酸激酶抑制剂预处理的 CML 患者的结果。
Cancer Med. 2023 Feb;12(3):2990-2998. doi: 10.1002/cam4.5212. Epub 2022 Sep 27.
5
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.加拿大真实世界中接受 asciminib 治疗的多线酪氨酸激酶抑制剂（TKI）治疗失败的慢性髓性白血病（CML）患者的经验。
Leuk Res. 2023 Oct;133:107374. doi: 10.1016/j.leukres.2023.107374. Epub 2023 Aug 22.
6
Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.阿斯科利尼布（Scemblix）：用于慢性期慢性髓性白血病伴或不伴T315I突变的三线治疗选择。
Am J Health Syst Pharm. 2023 Jan 5;80(2):36-43. doi: 10.1093/ajhp/zxac286.
7
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.ASCIMINIB 的特异性，一种治疗慢性髓性白血病的潜在药物，作为一种豆蔻酰口袋结合的 ABL 抑制剂，并分析其与 BCR-ABL1 激酶突变形式的相互作用。
Leuk Res. 2020 Nov;98:106458. doi: 10.1016/j.leukres.2020.106458. Epub 2020 Sep 29.
8
Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.阿伐替尼治疗费城染色体阳性慢性髓性白血病：聚焦患者选择与治疗结果
Cancer Manag Res. 2023 Aug 23;15:873-891. doi: 10.2147/CMAR.S353374. eCollection 2023.
9
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.阿西替尼对比博舒替尼治疗至少两种酪氨酸激酶抑制剂治疗后的慢性期慢性髓性白血病：ASCEMBL 的长期随访。
Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30.
10
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.STAMP 抑制剂 asciminib 对 T 细胞激活和代谢适应性的影响，与伊马替尼、达沙替尼和尼洛替尼的酪氨酸激酶抑制作用相比。
Cancer Immunol Immunother. 2023 Jun;72(6):1661-1672. doi: 10.1007/s00262-022-03361-8. Epub 2023 Jan 5.

本文引用的文献

1
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.慢性髓性白血病加速期和急变期的发病机制与管理
Leukemia. 2023 Jan;37(1):5-17. doi: 10.1038/s41375-022-01736-5. Epub 2022 Oct 29.
2
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.真实世界分析 ASCIMINIB 在接受过波那替尼预处理的慢性髓性白血病患者中的安全性和疗效。
Ann Hematol. 2022 Oct;101(10):2263-2270. doi: 10.1007/s00277-022-04932-6. Epub 2022 Aug 23.
3
The prevalence and prognosis of hyponatraemia in non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis.
非霍奇金淋巴瘤相关噬血细胞性淋巴组织细胞增生症中低钠血症的患病率和预后
Leuk Lymphoma. 2022 Feb;63(2):362-369. doi: 10.1080/10428194.2021.1992623. Epub 2021 Oct 18.
4
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.一项 3 期、开放标签、随机研究，评估了 STAMP 抑制剂 ASCiminib 与博舒替尼（一种二代 TKI）在 2 种或更多种 TKI 治疗后 CML 患者中的疗效。
Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984.
5
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.阿斯科利尼布治疗慢性髓性白血病患者在现实临床实践中的安全性和有效性。
Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8.
6
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.阿西替尼在 ABL 激酶抑制剂失败后的慢性髓性白血病中的应用。
N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.
7
Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.慢性髓性白血病中酪氨酸激酶抑制剂相关血液学不良事件的网络荟萃分析。
Br J Clin Pharmacol. 2019 Oct;85(10):2280-2291. doi: 10.1111/bcp.13933. Epub 2019 May 23.
8
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.伊马替尼作为慢性粒细胞白血病一线治疗的评估：随机CML研究IV的10年生存结果及非CML决定因素的影响
Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.
9
Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome.HScore 的制定与验证：一种用于诊断反应性噬血细胞综合征的评分系统。
Arthritis Rheumatol. 2014 Sep;66(9):2613-20. doi: 10.1002/art.38690.
10
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.BCR-ABL1 激酶结构域介导的耐药性对慢性髓性白血病的影响。
Leuk Res. 2014 Jan;38(1):10-20. doi: 10.1016/j.leukres.2013.09.011. Epub 2013 Sep 23.